South Korean companies’ production in Shanghai is expected to remain disrupted long on the lockdown to curb the spread of COVID-19, raising con...

SK Bioscience Co., a biopharmaceutical unit of South Korea’s SK Group, said on Friday it has acquired non-exclusive rights to sell US-based Nov...

South Korea approved exports of Moderna Inc.’s COVID-19 vaccine produced by Samsung Biologics Co. in a move that will help the country’s ...

South Korea’s reopening stocks surged on Dec. 3 as US President Joe Biden’s plans to curb the Omicron variant of COVID-19 exclude lockdow...

South Korea’s pharmaceutical giant Celltrion Inc. is set to export its COVID-19 treatment Regkirona to Europe by the end of this year as it see...

SK Inc., the investment and holding company of South Korea’s SK Group, is seeking to make COVID-19 treatment pills developed by Pfizer Inc. and...

South Korea’s pharmaceutical giant Celltrion Inc. has won final approval for its COVID-19 treatment Regkirona from the European Commission, a d...

Moderna Inc.’s COVID-19 vaccine first produced by Samsung Biologics Co. under a contract manufacturing organization (CMO) service will be avail...

South Korea’s Samsung Biologics Co. is gearing up for the drug substance (DS) sector of the messenger ribonucleic acid (mRNA)-based COVID-19 va...

South Korea's electronics and auto industries, the two main pillars of Asia’s fourth-largest economy, are losing growth momentum. Demand is slo...

The South Korean won tumbled to a near 11-month low as foreign investors dumped $6.1 billion in local stocks this week much more than their total sel...

SK Bioscience Co. has received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for phase 3 clinical trials of its COVID-19 ...

The South Korean government will invest 2.2 trillion won ($1.9 billion) by 2025 to become a top five vaccine producer in the world. President Moon Ja...

As concerns rise over a resurgence of the COVID-19 pandemic, the war for talent in South Korea’s pharmaceutical industry is intensifying as the...

South Korean biosimilar maker Celltrion Inc. will launch the first-phase clinical trials of its new COVID-19 treatment candidate next month, followin...

South Korea’s Samsung Biologics Co. posted its highest quarterly revenue and operating profit, thanks largely to a number of long-term manufact...

South Korea's economy reported strong growth on healthy private consumption in the second quarter, keeping expectations of an interest rate hike late...

South Korea’s biotechnology companies are releasing polymerase chain reaction (PCR) kits and equipment to detect COVID-19 infections within an ...

Celltrion Inc. on July 13 said that its COVID-19 treatment Regkirona has proven effective in reducing the incidence of severe cases of the virus by 7...

Multinational biopharmaceutical companies have dominated the world’s diagnostics market for years. However, the coronavirus pandemic, which sta...

Eyegene Inc. will be South Korea’s first vaccine maker to conduct clinical tests of messenger ribonucleic acid (mRNA) COVID-19 vaccines. Ealier...

South Korea will develop its own messenger ribonucleic acid (mRNA) vaccines by next year with plans to annually manufacture 100 million doses from 20...

German biopharmaceutical company CureVac N.V. may choose South Korea as one of its global production bases for the COVID-19 vaccine following Korean ...

SK Bioscience Co. has secured additional funding for phase III clinical trial of GBP510, its COVID-19 vaccine candidate jointly developed with the In...

Samsung Biologics Co. will be manufacturing the US company Moderna’s COVID-19 vaccine (mRNA-1273) from the second half of this year in Korea. A...

South Korea’s biosimilar and pharmaceutical companies are looking at a growing chance of emerging as a global hub for manufacturing vaccines fo...

Genexine Inc., one of the five South Korean pharmaceutical companies whose COVID-19 vaccine candidates have entered clinical trials, will export its ...

The aviation industry, one of the hardest-hit sectors by the global pandemic, is now whetting the appetite of South Korean private equity firms which...

South Korea’s SK Bioscience Co. is suspending production of SKYCellflu, an influenza vaccine, to focus on manufacturing COVID-19 vaccines inste...